Eli Lilly and Company’s Annual Declaration of Compliance for Purposes of California Health & Safety Code §§ 119400-119402

Lilly has developed a Comprehensive Compliance Program (CCP) in accordance with the requirements of California Health & Safety Code §§ 119400-119402. As of July 1, 2023, Lilly hereby declares in good faith that it is, in all material respects, in compliance with its CCP and the requirements of California Health & Safety Code §§ 119400-119402.

Lilly has developed and implemented elements of its CCP to address certain issues uniquely raised by the California law. In addition, compliance is a dynamic concept and, therefore, Lilly periodically assesses the effectiveness of its CCP and may modify aspects of the CCP to enhance it. Lilly assesses its CCP prior to July 1 of each year.

In making this declaration of compliance, Lilly is asserting that its CCP is reasonably designed to prevent and detect violations of law, regulations, and company policies, and provides for disciplinary and corrective actions when appropriate.

For a copy of this declaration of compliance and a description of Lilly’s CCP, call The Lilly Answers Center at 1-800LillyRx (1-800-545-5979).